HCG, Accenture Partner to Transform Cancer Research with AI
HealthCare Global Enterprises Limited (HCG), India’s largest cancer care network, has partnered with Accenture to transform cancer research and treatment using generative AI and deep learning. This strategic collaboration aims to accelerate precision medicine development in South Asia by analysing multi-dimensional and multi-omic patient data to enable earlier detection and more effective treatments for various cancers. A Data-Driven Approach to Cancer Care The initiative combines HCG’s clinical oncology expertise with Accenture’s global capabilities in AI, machine learning, and quantum computing to uncover molecular alterations with significant implications for patient care. The partnership, a first in South Asia, will leverage Accenture’s generative AI studios to drive innovation in drug discovery, biomarker identification, and treatment pathway development. Today, optimising cancer care necessarily calls for tech-driven advancements in research and academics, especially for ensuring seamless, error-free data collection and streaming. Given the heterogenicity of tumor genomics and other forms of omics, AI has become integral to precise, personalised medical advancements. Highlighting the initiative’s significance, Dr. B.S. Ajaikumar, executive chairman of HCG, said cancer care today is necessitated by technological advancement, and collaborations can enhance the research and service offerings. “Accenture’s deep expertise in technology and analytics, leveraging AI modeling, will help us enhance our research aimed at developing patient-centric therapies with lasting outcomes,” he said. Advanced technologies such as image analysis software, informatics, and novel algorithms are used to study cancer data and create new insights into cancer biology. Initial efforts focus on identifying molecular signatures for lung adenocarcinoma and head and neck cancers, which will later extend to other cancer types. The program also seeks to enhance understanding of cancer development, origins, and symptoms, advance treatment algorithms for precision medicine, and improve therapy outcomes. Senthil Ramani, global lead of data and AI at Accenture, remarked that next-gen computing, including generative AI, combined with deep biological and clinical expertise, can play a pivotal role in cancer research. “Together with HCG, we are blending our global expertise in data and AI along with life sciences R&D to rapidly and accurately improve decision-making for the treatment and care for cancer patients in South Asia, and across the world,” Ramani said. AI has been making significant strides in healthcare, and big tech companies are investing heavily in the sector. NVIDIA, Microsoft and Google, have all been focusing on leveraging generative AI for functions such as report reading, summarisation, drug discovery and many other activities.
This partnership will leverage Accenture’s generative AI studios to drive innovation in drug discovery, biomarker identification, and treatment pathway development.
This partnership will leverage Accenture’s generative AI studios to drive innovation in drug discovery, biomarker identification, and treatment pathway development.
["Accenture", "AI", "Cancer research", "drug discovery", "HCG"]
["Accenture", "Go", "HCG", "machine learning", "AI", "Cancer research", "ML", "RAG", "Aim", "deep learning", "drug discovery", "analytics", "generative AI", "R"]
["AI", "machine learning", "ML", "deep learning", "analytics", "generative AI", "Aim", "RAG", "R", "Go"]
As a rare blend of engineering, MBA, and journalism degree, Vandana Nair brings a unique combination of technical know-how, business acumen, and storytelling skills to the table. Her insatiable curiosity for all things startups, businesses, and AI technologies ensures that there's always a fresh and insightful perspective to her reporting. She now hosts her tech segment 'Point Break' on AIM Tv.